Abnormalities in the oestrous cycle in the mare

Sudden Death by Ovarian Hemorrhage and Hemoperitoneum in a Pregnant Miniature Mare

This report describes a case of sudden death of a pregnant miniature mare due to an acute ovarian hemorrhage leading to fatal hemoperitoneum. The miniature horse was a 12-year-old female, 60 days pregnant, with a body condition score of 7 (1-9), with a history of obesity and laminitis. Necropsy revealed hemoperitoneum due to an ovarian capsule rupture and hemorrhage after a physiological supplementary ovulation and luteinization. Ovarian rupture after ovulation is uncommon in mares.

Reproductive performance of donor mares subsequent to eFSH treatment in early vernal transition: Comparison between the first, second, and mid-season estrous cycles of the breeding season

The objective was to compare the reproductive performances associated with the first (Cycle-1), second (Cycle-2), and mid-season (MS-Cycle) ovulations of the breeding season in donor mares that were treated with equine-FSH (eFSH) in the early vernal transition. Mares (n=15) kept under ambient light were examined ultrasonographically per-rectum starting January 30. When an ovarian follicle > or =25mm in diameter was detected, twice daily eFSH treatments were initiated. The eFSH treatments ceased when a follicle > or =35mm was detected, and 36h later hCG was administered. Thereafter, mares were artificially inseminated every 48h until ovulation (Day 0). Trans-cervical embryo recovery attempts were performed on Day 8, and subsequently PGF2alpha was administered. Equine FSH was not administered in the subsequent estrous cycles. In Cycle-2 and in the MS-Cycle, hCG was administered when a follicle > or =35mm was detected; breeding, embryo recovery, and PGF2alpha administration, were similar to Cycle-1. Mares had an untreated estrous cycle (no treatment or breeding) between Cycle-2 and the MS-Cycle. All mares developed follicle(s) > or =35mm after 4.9+/-0.6 days of eFSH treatment, and subsequently ovulations occurred; mean (95% CI) interval from treatment initiation to ovulation was 7.9 (6.5-9.3) days. The number of preovulatory follicles (> or =30mm) at the time of hCG administration (Cycle-1: 2.2+/-0.3 compared with Cycle-2: 1.0+/-0 compared with MS-Cycle: 1.1+/-0.1 follicles), and the number of ovulations (2.5+/-0.4 compared with 1.0+/-0 compared with 1.1+/-0.1 ovulations) were greater (p<0.05) in Cycle-1. Nevertheless, mean embryo numbers did not differ among cycles (0.8+/-0.2 compared with 0.5+/-0.1 compared with 0.5+/-0.1 embryo/mare). On average, embryo morphology grade was less (p<0.05) in Cycle-1 as compared to non-eFSH cycles (combined Cycle-2 and MS-Cycle). This impaired embryo quality could be due to a seasonal effect, or negative effect of the eFSH treatment, which was possibly related to alterations in the hormonal environment (estradiol-17beta and progesterone). A prolonged IOI (>21 days) was recorded in 7 of 15 mares following the Cycle-1 ovulation, but not subsequently. In conclusion, eFSH treatment of vernal transitional donor mares stimulated ovulation within only few days of treatment, and the following embryo recovery rate was at least as good as in the subsequent estrous cycles; however, on average, embryos were morphologically impaired. In subsequent estrous cycles in the breeding season, ovulations, embryo recovery rates, and embryo variables did not appear to be negatively affected; however, the first inter-ovulatory interval of the breeding season was prolonged in approximately half of the mares.

Prolonged luteal activity in mares--a semantic quagmire

Prolonged luteal activity is one of the most formidable terminology challenges in mare reproductive biology. Prolonged luteal activity can be a result of persistence of an individual corpus luteum or the sequential development of luteal glands, each of which may have a normal life span. Luteal tissue can originate from an unovulated follicle or from an ovulation occurring during either follicular or luteal dominance. These complexities, together with ambiguous and inconsistent terminology, have resulted in confusion regarding those conditions which can be grouped broadly under the term prolonged luteal activity. Persistence of an individual corpus luteum can occur in association with severe damage to the endometrium resulting in loss of the uterine luteolytic mechanism. Spontaneous (no known uterine pathology) persistence of the corpus luteum from the follicular-phase ovulation has not been documented adequately as a clinical entity. The occurrence of ovulation towards the end of dioestrus may cause confusion about the origin of prolonged luteal activity. Such immature dioestrous corpora lutea may not respond to the release of uterine luteolysin, thereby leading to prolonged luteal activity even though the original corpus luteum regressed at the normal time. In the absence of critical monitoring of the corpus luteum (eg by ultrasound) the prolonged activity could be attributed erroneously to persistence of the corpus luteum from the follicular-phase ovulation. Pseudopregnancy is another confusing term that is sometimes used to describe persistence of the corpus luteum, especially when the luteal persistence is caused by embryonic loss after the embryo has blocked the uterine luteolytic mechanism.(ABSTRACT TRUNCATED AT 250 WORDS)